Re­silience forges JV with MD An­der­son, ready­ing new cell ther­a­pies for can­cer

The Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter and con­tract bi­o­log­ic man­u­fac­tur­er Re­silience are crack­ing open a new part­ner­ship, seek­ing to ac­cel­er­ate the de­vel­op­ment and man­u­fac­tur­ing of cell ther­a­pies for can­cer pa­tients.

The so-called Cell Ther­a­py Man­u­fac­tur­ing Cen­ter will be based in a 60,000-square-foot fa­cil­i­ty in down­town Hous­ton. With a team of 70 em­ploy­ees, the cen­ter will fo­cus on process and an­a­lyt­i­cal de­vel­op­ment as well as ear­ly-phase and clin­i­cal-stage GMP.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN